ArticleClinical and experimental immunology2011
Induction of β-defensins by l-isoleucine as novel immunotherapy in experimental murine tuberculosis.
Article in Clinical and experimental immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 76 citations in OpenAlex.
- Branched-chain amino acids and gut microbiota: coregulation and impact on neurological function via the gut-brain axis.Gut microbes · 2026Review
- Discovery and Profiling of Protein CysteineMolecules (Basel, Switzerland) · 2025Article
- Immunotherapy for tuberculosis: current strategies and future directions.Military Medical Research · 2025Review
- Plasma branched-chain amino acids and risk of radiation-induced acute skin toxicity in women with breast cancer: results from the ATHENA project.Frontiers in oncology · 2025Article
- BCAAs acutely drive glucose dysregulation and insulin resistance: role of AgRP neurons.Nutrition & diabetes · 2024Article
- Mycobacterium tuberculosis suppresses host antimicrobial peptides by dehydrogenating L-alanine.Nature communications · 2024Article
- Adverse Health Effects of the Long-Term Simultaneous Exposure to Arsenic and Particulate Matter in a Murine Model.Journal of toxicology · 2024Article
- Integration of serum metabolomics and network pharmacology reveals the immunoenhancing mechanisms of Qishenbuqi capsules.Toxicology research · 2023Article
- Induction of Endogenous Antimicrobial Peptides to Prevent or Treat Oral Infection and Inflammation.Antibiotics (Basel, Switzerland) · 2023Review
- Review
- Recent Advances in Host-Directed Therapies for Tuberculosis and Malaria.Frontiers in cellular and infection microbiology · 2022Review
- Antimicrobial Peptides as Potential Anti-Tubercular Leads: A Concise Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Effects of different branched-chain amino acids supplementation protocols on the inflammatory response of LPS-stimulated RAW 264.7 macrophages.Amino acids · 2021Article
- Human RNase3 immune modulation by catalytic-dependent and independent modes in a macrophage-cell line infection model.Cellular and molecular life sciences : CMLS · 2021Article
- Targeting Molecular Inflammatory Pathways in Granuloma as Host-Directed Therapies for Tuberculosis.Frontiers in immunology · 2021Review
- Amino acids and the regulation of oxidative stress and immune function in dairy cattle.Journal of animal science · 2020Article
- Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.Frontiers in immunology · 2020Review
- A Multi-Omics Study of Chicken Infected by Nephropathogenic Infectious Bronchitis Virus.Viruses · 2019Article
- Recent Progress on Branched-Chain Amino Acids in Obesity, Diabetes, and Beyond.Endocrinology and metabolism (Seoul, Korea) · 2019Review
- Potentials of Host-Directed Therapies in Tuberculosis Management.Journal of clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis is a worldwide health problem, and multidrug-resistant (MDR) and extensively multidrug-resistant (XMDR) strains are rapidly emerging and threatening the control of this disease. These problems motivate the search for new treatment strategies. One potential strategy is immunotherapy using cationic anti-microbial peptides. The capacity of l-isoleucine to induce beta-defensin expression and its potential therapeutic efficiency were studied in a mouse model of progressive pulmonary tuberculosis. BALB/c mice were infected with Mycobacterium tuberculosis strain H37Rv or with a MDR clinical isolate by the intratracheal route. After 60 days of infection, when disease was in its progressive phase, mice were treated with 250 µg of intratracheal l-isoleucine every 48 h. Bacillary loads were determined by colony-forming units, protein and cytokine gene expression were determined by immunohistochemistry and reverse transcription-quantitative polymerase chain reaction (RT-qPCR), respectively, and tissue damage was quantified by automated morphometry. Administration of l-isoleucine induced a significant increase of beta-defensins 3 and 4 which was associated with decreased bacillary loads and tissue damage. This was seen in animals infected with the antibiotic-sensitive strain H37Rv and with the MDR clinical isolate. Thus, induction of beta-defensins might be a potential therapy that can aid in the control of this significant infectious disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.